Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AstraZeneca
Participants will be asked whether they agree to participate in the measurements of arterial stiffness. Participants who agree will be included in the substudy, with the target of 60 patients with arterial stiffness measurements to complete the trial.
Study was terminated due to difficulty in identifying further eligible patients for this exploratory study within a reasonable time.
Age
40–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Written informed consent (IC)
Age ≥ 40 years
History of COPD for at least 12 months prior to enrollment (Visit V0)
Chronic productive cough for 3 months in each of the 2 years prior to enrollment (if other causes of productive cough have been excluded) and/or an exacerbation with predominantly bronchitic symptoms at enrollment
Presentation of an acute exacerbation of COPD that will be associated with increased sputum volume or change in sputum colour
Documented fixed airway obstruction determined by an FEV1/FVC ratio (post-bronchodilator) \< 70% (if a pulmonary function test is not possible at Visit V0 a previous measurement can be taken which must not be older than 6 months)
Former smoker (defined as: smoking cessation at least 1 year ago) or current smoker both with a smoking history of at least 10 pack years
You may not be if
Diagnosis of asthma and/or other relevant lung disease
Known alpha-1-antitrypsin deficiency
Recurrent exacerbations (within 8 weeks of a preceding exacerbation)
Treatment of current exacerbation with oral corticosteroids and/or antibiotics already started at enrollment
Treatment with PDE4 inhibitors within 3 months prior to Visit V0
